Recent groundbreaking research into canine heart disease is changing the way we treat one of the most common heart conditions.
It is estimated that one dog in ten may suffer from some type of heart disease.
There is a particular type of heart disease called mitral valve disease that can lead to congestive heart failure, reduced quality of life and an overall shortened lifespan.
The EPIC (Evaluation of Pimobendan In dogs with Cardiomegaly) Study was the largest veterinary cardiology study in history. This groundbreaking study set out to answer a key question: Can a particular drug (pimobendan) delay the onset of congestive heart failure (CHF) in dogs with mitral valve disease?
The study, which began in 2010 and ran through to 2015, included investigators at 36 study centres in 11 nations across 4 continents. Investigators were held to rigorous scientific standards, and an independent team compiled and reported the findings.
The results concluded that dogs who received pimobendan experienced a 15-month delay in onset of clinical signs of CHF, cardiac-related death, or euthanasia. Some have described these results as 'epic' (pardon the pun!)
And the best news is that with x-rays and an ultrasound of the heart, along with the guidelines from the results of this study, we are now able to determine which of our patients with mitral valve disease will benefit from medication and which can be placed on a monitoring program. This means we can help your pet live a longer and healthier life.
If you have any questions about the management of heart disease the Pet Guardians team are here to help!